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The European Society for Medical Oncology (ESMO) consensus conference on mature B-cell lymphomas and chronic
lymphocytic leukaemia (CLL) was held on 20 June 2015 in Lugano, Switzerland, and included a multidisciplinary panel of
25 leading experts. The aim of the conference was to develop recommendations on critical subjects difficult to consider in
detail in the ESMO Clinical Practice Guidelines. The following areas were identified: (i) the elderly patient, (ii) prognostic
factors suitable for clinical use and (iii) the ‘ultra-high-risk’ group. Before the conference, the expert panel was divided into
three working groups; each group focused on one of these areas in order to address four clinically relevant questions re-
lating to that topic. All relevant scientific literature, as identified by the experts, was reviewed in advance. During the con-
sensus conference, each working group developed recommendations to address each of the four questions assigned to
their group. These recommendations were then presented to the entire panel and a consensus was reached. This manu-
script presents recommendations dedicated to the second area of interest, i.e. prognostic factors suitable for clinical use.
The four topics [i.e. interim positron emission tomography (PET), TP53mutations, cell of origin (COO) and minimal residual
disease (MRD)] were primarily chosen because of the bulk of available data together with the lack of clear guidance
regarding their use in clinical practice and within clinical trials. Results, including a summary of evidence supporting each
recommendation, are detailed in this manuscript. The panel acknowledged that detection of TP53 inactivation by deletion
or mutation in CLL should be implemented in clinical practice (level of evidence I, strength of recommendation A). Due to
their potentially high prognostic value, at least in some lymphoma entities, implementation of interim PET, COO and MRD
was highly recommended in the context of clinical trials. All expert panel members approved this final article.
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introduction
Laboratory-based and imaging tools are increasingly used in
patients with lymphoid malignancies to better understand their
prognosis and even to guide therapeutic decisions. Despite their
documented predictive value in several specific settings, their
use is often extended to conditions where there is little evidence
of substantial therapeutic benefit. This could result in an
increase in costs and inappropriate therapeutic decisions. As
such, clear recommendations regarding the use of these tools
are required.
In 2015, the European Society for Medical Oncology (ESMO)
held a consensus conference on mature B-cell neoplasms and
chronic lymphocytic leukaemia (CLL) in order to develop
recommendations on critical subjects that were difficult to†See the appendix for members of the ESMO Lymphoma Consensus Conference.
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consider in detail in the ESMO Clinical Practice Guidelines
(CPG). In this consensus conference, one of the working groups
(Working Group 2) focused on prognostic factors suitable for
clinical use. As such, the objectives of this working group were:
(i) to identify a restricted number of prognostic tools whose clin-
ical use is established or under rapid technological development;
(ii) to discuss the technical and clinical reliability of these prog-
nosticators; (iii) to consider the prognostic value of these tools;
(iv) to provide recommendations on the use of these prognostica-
tors in the context of clinical research and routine practice.
Here, we describe the recommendations developed by Working
Group 2 and approved by the whole panel, and provide a
summary of evidence supporting each recommendation.
methods
A consensus panel, comprising a multidisciplinary panel of 25
experts in the management of lymphoma, was convened by
ESMO. Three consensus conference chairs (CB, ML, MH) were
also appointed. The consensus panel was divided into three
working groups, each of which was assigned a specific subject
area and a working group chair as follows: Working Group 1:
the elderly patient (Chair: CB); Working Group 2: prognostic
factors suitable for clinical use (Chair: ML); Working Group 3:
the ‘ultra-high-risk’ group (Chair: MH). The consensus confer-
ence was held on 20 June 2015 in Lugano, Switzerland. Before
this consensus conference, four clinically relevant questions
were identified for each subject area.
A literature review was conducted by each working group
before the consensus conference, with each group responsible
for compiling a summary of relevant information required to
develop recommendations relating to each of their questions at
the conference. No systematic literature search was undertaken.
During the conference, in parallel sessions, the three working
groups discussed and agreed on recommendations relating to
each of their assigned questions. The level of evidence and
strength of each recommendation were also noted, which were
defined based on the ‘Infectious Diseases Society of America-
United States Public Health Service Grading System’, as shown
in Table 1 [1]. Recommendations from each group were then
presented to the entire panel of experts, where they were dis-
cussed and modified, as required. Finally, a vote was conducted
to determine the level of agreement among the expert panel for
each of the recommendations. Discussion regarding each of the
recommendations was completed after the consensus meeting,
with additional supporting evidence published after the meeting
also included in the final manuscript.
For Working Group 2, which is the focus of this report, four
prognostic tools were identified for discussion in terms of their
potential suitability as prognostic tools for clinical use.
Discussions focused on B-cell lymphoma and CLL; plasma cell
disorders and T-cell lymphoma were considered outside the
scope of this consensus conference. In addition, working group
members were asked to focus on disease entities in which the
prognostic tools were most promising and where a greater need
for clinical recommendations was required (front-runner entities,
FRE). As such, the following prognostic tools and associated
disease entities of specific interest were considered:
(i) interim positron emission tomography [PET; FRE:
Hodgkin’s lymphoma (HL), diffuse large B-cell lymphoma
(DLBCL)],
(ii) TP53mutations and deletions (FRE: CLL),
(iii) cell of origin (COO) determination by gene expression
profiling (GEP) or immunohistochemistry (IHC) (FRE:
DLBCL),
(iv) molecular-based minimal residual disease (MRD) evalu-
ation [FRE: mantle cell lymphoma (MCL); follicular
lymphoma (FL), CLL]
Results from the section of the consensus conference dedi-
cated to prognostic factors suitable for clinical use, together with
a summary of evidence supporting each recommendation, are
detailed in this article. A summary of these recommendations is
shown in Table 2. Importantly, these additional recommenda-
tions should be read in conjunction with the already-published
ESMO CPGs for the diagnosis, treatment and follow-up of
malignant lymphomas and CLL [2–6].
results
1. Interim PET as a prognostic tool
18-F-fluorodeoxyglucose (FDG)-PET has recently been recom-
mended as the standard tool for the evaluation, staging and re-
sponse assessment for patients with FDG-avid lymphomas,
including HL, DLBCL and FL [7]. With the use of FDG-PET,
metabolic response has increasingly been acknowledged as one of
Table 1. Levels of evidence and grades of recommendation
(adapted from the Infectious Diseases Society of America-United
States Public Health Service Grading Systema)
Levels of evidence
I Evidence from at least one large randomised, controlled trial of
good methodological quality (low potential for bias) or meta-
analyses of well-conducted randomised trials without
heterogeneity
II Small randomised trials or large randomised trials with a suspicion
of bias (lower methodological quality) or meta-analyses of such
trials or of trials with demonstrated heterogeneity
III Prospective cohort studies
IV Retrospective cohort studies or case–control studies
V Studies without control group, case reports, experts’ opinions
Grades of recommendation
A Strong evidence for efficacy with a substantial clinical benefit,
strongly recommended
B Strong or moderate evidence for efficacy but with a limited clinical
benefit, generally recommended
C Insufficient evidence for efficacy or benefit does not outweigh the
risk or the disadvantages (adverse events, costs,…), optional
D Moderate evidence against efficacy or for adverse outcome,
generally not recommended
E Strong evidence against efficacy or for adverse outcome, never
recommended
aBy permission of the Infectious Diseases Society of America [1].
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Table 2. Summary of recommendationsa
Guidelines statement LoE GoR
1. The potential role of interim PET as a prognostic tool
Recommendations
1.1 The exploratory use of interim FDG-PET as a surrogate test of chemosensitivity and as a diagnostic tool to
facilitate clinical decision-making is encouraged in clinical trials in HL, DLBCL and other aggressive FDG-avid
lymphoma entities
III B
1.2 There are little published data from randomised trials to support the use of an interim PET-driven
therapeutic strategy in HL, DLBCL or other FDG-avid lymphomas. However, preliminary data strongly support
the use of interim PET to tailor therapy in individual cases. On these grounds, results of interim PET may be
applied in individual patients with early or advanced HL
II C
1.3 Based on the lack of therapeutic consequences, the routine clinical use of interim PET is not recommended
in patients with DLBCL
II D
1.4 Based on the lack of data, the routine use of interim PET as a decision tool is discouraged in non-HL, non-
DLBCL, FDG-avid lymphoma entities
V E
2. The potential role of TP53mutations and deletions as a prognostic tool
Recommendations
2.1 Given the well-established, prognostic and predictive value of TP53 disruption in CLL, the panel strongly
recommends the inclusion of TP53 analysis, both by FISH and DNA sequencing, in clinical trials of CLL for
intervention and monitoring purposes. In particular, the availability of new drugs that overcome TP53-mediated
chemorefractory disease mandates the acquisition of TP53 status for all patients with CLL at the time of screening
procedures in trials in which one or more arms may be based on drugs that are known to be ineffective in TP53-
disrupted CLL. Therefore, the use of TP53 screening for monitoring and intervention in clinical trials is
encouraged in CLL
I A
2.2 In other lymphoid neoplasms, TP53 screening for investigational purposes is neither recommended nor
discouraged. At present, the panel discourages clinical trials aimed at specific interventions based on TP53 status
unless prognostic markers are the major focus of the trial and the drug being evaluated has a strong biological
rationale for overcoming TP53-mediated resistance
V C (investigation);
D (intervention)
2.3 In CLL, the panel supports analysis of TP53 disruption at the time of treatment requirement, both in first-
line and subsequent lines of therapy. Reassessing TP53 status in previously TP53 wild-type CLL at relapse
requiring treatment is relevant since TP53 disruption may develop, or become detectable only at relapse. In
routine practice, characterising TP53 status in a given patient with CLL is clinically relevant as this may affect
treatment decisions. The use of TP53 screening by FISH and mutational analysis for monitoring and intervention
in clinical practice is therefore encouraged in CLL, provided there is availability of and access to therapies
overcoming TP53-mediated resistance (e.g. inhibitors of the B-cell receptor and allo-SCT)
I A
2.4 In other lymphoid neoplasms, the panel discourages the use of TP53 outside of clinical trials as there is no
general recommendation for treatment modification currently published. The results of currently recruiting trials
might modify this attitude in the coming years
V E
3. The potential role of COO determination by IHC or GEP as a prognostic tool
Recommendations
3.1 Given the limitations of IHC, the panel does not encourage its use in prospective clinical trials for
prognostication
I C
3.2 Given the limitations of IHC, the panel discourages its use in prospective clinical trials to guide intervention I D
3.3 The panel strongly encourages the use of GEP in prospective clinical trials for prognostication I A
3.4 Clinical trials of interventions based on GEP results are encouraged I B
3.5 Based on inadequate standardisation, and a lack of well-designed interventional studies, the use of COO
determination by IHC or GEP in DLBCL is generally not recommended in routine clinical practice outside of
clinical trials
V D
4. The potential role of molecular-based MRD evaluation as a prognostic tool
Recommendations
4.1 The use of MRD evaluation for monitoring and intervention in clinical trials is encouraged in MCL, FL and
CLL
(i) MCL: for monitoring I B
(ii) MCL: for intervention III C
(iii) FL: for monitoring I B
(iv) FL: for intervention IV C
(v) CLL: for monitoring (depends on the drug used) I B
(vi) CLL: for intervention IV C
Continued
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the strongest available prognostic tools and has been identified as
a surrogate test for chemosensitivity. For the purposes of this con-
sensus manuscript, the definition of interim PET applies to any
FDG-PET carried out during a planned systemic treatment,
usually after 2–4 cycles in the case of a conventional chemother-
apy programme, or after 2–4 cycles of reinduction chemotherapy
before the administration of a planned high-dose chemotherapy
followed by stem cell support where intensified regimens are used.
In HL and DLBCL, the identification of metabolic response
during treatment has been correlated with the individual risk of
relapse, and of death in some cases, and has the potential to
improve patient outcome through the early adaptation of treat-
ment intensity [8–12]. There is general consensus that the
achievement of an early metabolic response during treatment is
predictive of favourable outcomes in terms of both progression
and overall survival (OS). The high negative predictive value of
interim PET, however, is counterbalanced by a variable rate of
false-positive results that are usually more common in DLBCL
than in HL [13].
methodological considerations
broad availability: Although FDG-PET is broadly available
in high-income and in some middle-income countries, it
remains inaccessible for many patients. As such, access to FDG-
PET still needs to be improved worldwide.
reproducibility and standardisation: Reproducibility of FDG-
PET has markedly improved with the application of
standardised and recommended methods, particularly with
the use of the Deauville 5-point scale (5PS) [14–17] [III, B].
However, quality assurance and training programmes are still
needed. The application of semi-quantitative measurements of
interim PET [i.e. delta standardised uptake value (SUV) max] is
not recommended, although data suggest it may add prognostic
detail in DLBCL [18].
clarity of reporting system: Currently, routine clinical reports
are not well standardised. The panel recommends documenting
the 5PS and SUV of the main lesions in the interim FDG-PET
report of patients receiving front-line treatment [19].
prognostic value
The panel was confident of the high prognostic value of
interim FDG-PET when used during induction therapy with
doxorubicin/bleomycin/vinblastine/dacarbazine (ABVD) (after
1–3 cycles) in immunocompetent and human
immunodeficiency virus (HIV)-negative patients with classical
HL [II, A] [8, 12, 15, 20–25].
The panel was also confident of the prognostic value of
interim FDG-PET when used during induction therapy with
anthracycline-containing regimens (after 2–4 cycles) in im-
munocompetent and HIV-negative patients with DLBCL [III, A]
[11, 13, 16, 18, 26–29].
Finally, the panel recognised that interim FDG-PET is prog-
nostic when used after reinduction chemotherapy and before a
preplanned high-dose therapy programme in relapsed or refrac-
tory HL and DLBCL [III, A] [9, 10, 30–36].
panel recommendations for the use of interim PET for
monitoring and intervention in clinical trials
recommendation 1.1: The exploratory use of interim FDG-
PET as a surrogate test of chemosensitivity and as a diagnostic
tool to facilitate clinical decision-making is encouraged in
clinical trials in HL, DLBCL and other aggressive FDG-avid
lymphoma entities.
Level of evidence: III
Strength of recommendation: B
Consensus: 100% yes (23 voters)
panel recommendations for the use of interim PET for
monitoring and intervention in routine clinical practice
recommendation 1.2: There are little published data from
randomised trials to support the use of an interim PET-driven
therapeutic strategy in HL, DLBCL or other FDG-avid
lymphomas. However, preliminary data strongly support the use
of interim PET to tailor therapy in individual cases. On these
grounds, results of interim PET may be applied in individual
patients with early or advanced HL [20–22, 25, 37–40].
Level of evidence: II
Strength of recommendation: C
Consensus: 100% yes (23 voters)
recommendation 1.3: Based on the lack of therapeutic
consequences, the routine clinical use of interim PET is not
recommended in patients with DLBCL [13].
Level of evidence: II
Strength of recommendation: D
Consensus: 100% yes (23 voters)
Table 2. Continued
Guidelines statement LoE GoR
4.2 The use of MRD evaluation for monitoring and intervention in clinical practice is not recommended in
MCL, FL and CLL, with the exception of monitoring after allo-SCT
V D
aThere was 100% consensus from the panel of experts for all recommendations listed.
LOE, level of evidence; GOR, grade of recommendation; allo-SCT, allogeneic haematopoietic stem cell transplantation; CLL, chronic lymphocytic
leukaemia; COO, cell of origin; DLBCL, diffuse large B-cell lymphoma; DNA, deoxyribonucleic acid; FDG, fluorodeoxyglucose; FISH, fluorescence in situ
hybridisation; FL, follicular lymphoma; GEP, gene expression profiling; HL, Hodgkin’s lymphoma; IHC, immunohistochemistry; MCL, mantle cell
lymphoma; MRD, minimal residual disease; PET, positron emission tomography.
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recommendation 1.4: Based on the lack of data, the routine
use of interim PET as a decision tool is discouraged in non-HL,
non-DLBCL, FDG-avid lymphoma entities.
Level of evidence: V
Strength of recommendation: E
Consensus: 100% yes (23 voters)
2. The potential role of TP53mutations and
deletions as a prognostic tool
The tumour suppressor gene TP53 maps at 17p13 and codes for
a central regulator of the deoxyribonucleic acid (DNA) damage-
response pathway; its activation leads to cell cycle arrest and
DNA repair, apoptosis or senescence [41, 42]. In lymphoid ma-
lignancies, TP53 may be disrupted by chromosomal deletions,
mutations or a combination of both. Overall, 95% of mutations
are localised within the central DNA binding domain of TP53,
impairing DNA binding and transactivation of target genes
[41–43]. Deletion of the TP53 locus at 17p13 is detectable by
fluorescence in situ hybridisation (FISH), while identification of
TP53 mutations requires DNA sequencing, either Sanger se-
quencing or next-generation sequencing. The frequency of TP53
disruption at the time of diagnosis varies across different types
of lymphoid malignancies, and may progressively increase at the
time of relapse or development of chemorefractory disease, as
clearly documented in the case of CLL [44]. The fact that TP53
disruption may be acquired during the disease course is import-
ant from a diagnostic perspective, requiring, where clinically
indicated, the sequential analysis of the locus at each time of
treatment requirement [45–48]. The clinical importance of
TP53 abnormalities in lymphoid malignancies is best demon-
strated in the case of CLL, where TP53 disruption is tightly
linked to the poor prognosis marked by this genetic lesion and
its close association with chemorefractory disease, as documen-
ted by a number of observational studies and prospective trials
conducted both in the chemotherapy and immuno-chemother-
apy eras [49–55]. However, there is evidence that TP53 disrup-
tion predicts an adverse outcome also in other mature B-cell
neoplasms [56, 57].
methodological considerations
broad availability: A complete analysis of TP53 disruption
requires the availability of both FISH and DNA sequencing.
Analysis of TP53 deletion by FISH is widely available in many
haematological referral centres as well as in diagnostic
laboratories dedicated to genetic disorders. Conversely, analysis
of TP53 mutations by Sanger sequencing is currently restricted
to highly specialised centres, and is not widely available. The
panel agrees that, at least in the context of CLL, a complete
analysis of TP53 disruption, including analysis of TP53
mutations, should be prioritised because TP53 disruption is the
only well-established genetic marker which requires adaptation
of treatment in CLL [45–48].
reproducibility and standardisation: FISH analysis for
del17p13 is considered a well-standardised and reproducible
technique. Sanger sequencing analysis for TP53 mutations is
technically well standardised and adequately reproducible in
experienced laboratories. Until recently, inter-laboratory
reproducibility has not been systematically assessed. However,
the European Research Initiative on CLL (ERIC) has now
implemented a quality control initiative for TP53 mutations in
many centres in Europe [58].
clarity of reporting system: Currently, there is no standardised
reporting system for TP53 analysis across different centres.
Data derived from randomised trials supporting these
recommendations were obtained using a cut-off for FISH of
10%–20% of positive cells by Sanger sequencing. Regarding
TP53 mutation analysis, the cut-off for mutation detection by
Sanger sequencing can be generally estimated at 15%–20% of
positive cells, although it may vary according to the precise
nucleotide position and sequence. Inter-observer variability in
the interpretation of electropherograms may also affect the
detection threshold of Sanger sequencing; the use of dedicated
software for mutation detection may reduce, at least in part,
such variability. The precise description of TP53 mutations
should be documented according to the well-codified Human
Genome Variation Society (HGVS) nomenclature system (www.
hgvs.org/mutnomen). Mutations also need to be validated
through the International Agency for Research on Cancer
(IARC) TP53 database (p53.iarc.fr). The GenBank reference
sequence used for mutation detection should also be clearly
stated in diagnostic reports.
prognostic value
The panel is confident with the general prognostic and
predictive value of TP53 disruption in CLL [I, A]. The panel is
also confident with the general prognostic value of TP53
disruption in other diseases, namely MCL, DLBCL and FL [II, B].
Many studies, both prospective and retrospective, have
demonstrated that TP53 disruption is associated with a poor
prognosis in CLL [48–55]. In particular, the CLL8 trial of the
German CLL Study Group clearly documented that both
del17p13 and TP53 mutation identify a very high-risk category
of patients with CLL who were treated with fludarabine/cyclo-
phosphamide/rituximab (FCR), an immuno-chemotherapy
regimen that is the gold standard first-line treatment for fit patients
with CLL [51, 55]. Notably, the poor prognosis associated with
TP53 disruption in CLL appears to be independent of the che-
motherapeutic agents utilised [48–55]. However, this might poten-
tially change when non-genotoxic drugs, such as ibrutinib,
idelalisib and venetoclax, become part of routine practice.
panel recommendations for molecular and cytogenetic analysis of
TP53 disruption in CLL and other lymphoid neoplasms for
monitoring and intervention in clinical trials
recommendation 2.1: Given the well-established, prognostic
and predictive value of TP53 disruption in CLL, the panel
strongly recommends the inclusion of TP53 analysis, both by
FISH and DNA sequencing, in clinical trials of CLL for
intervention and monitoring purposes. In particular, the
availability of new drugs that overcome TP53-mediated
chemorefractory disease mandates the acquisition of TP53
status for all patients with CLL at the time of screening
procedures in trials in which one or more arms may be based on
drugs that are known to be ineffective in TP53-disrupted CLL
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[58–62]. Therefore, the use of TP53 screening before the start of
treatment is highly encouraged in CLL.
Level of evidence: I
Strength of recommendation: A
Consensus: 100% yes (23 voters)
recommendation 2.2: In other lymphoid neoplasms, TP53
screening for investigational purposes is neither recommended
nor discouraged. At present, the panel discourages clinical trials
aimed at specific interventions based on TP53 status unless
prognostic markers are the major focus of the trial and the drug
being evaluated has a strong biological rationale for overcoming
TP53-mediated resistance.
Level of evidence: V
Strength of recommendation for investigation: C
Strength of recommendation for intervention: D
Consensus: 100% yes (23 voters)
panel recommendations for molecular and cytogenetic analysis of
TP53 disruption in CLL and other lymphoid neoplasms for
monitoring and intervention in clinical practice outside of
clinical trials
recommendation 2.3: In CLL, the panel supports analysis of
TP53 disruption at the time of treatment requirement, both in
first-line and subsequent lines of therapy. Reassessing TP53
status in previously TP53 wild-type CLL at relapse requiring
treatment is relevant since TP53 disruption may develop, or
become detectable only at relapse. In routine practice,
characterising TP53 status in a given patient with CLL is
clinically relevant as this may affect treatment decisions. The use
of TP53 screening by FISH and mutational analysis for
monitoring and intervention in clinical practice is therefore
encouraged in CLL, provided there is availability of and access
to therapies overcoming TP53-mediated resistance [e.g.
inhibitors of the B-cell receptor and allogeneic haematopoietic
stem cell transplantation (allo-SCT)].
Level of evidence: I
Strength of recommendation: A
Consensus: 100% yes (23 voters)
recommendation 2.4: In other lymphoid neoplasms, the
panel discourages the use of TP53 outside of clinical trials as
there is no general recommendation for treatment modification
currently published. The results of currently recruiting trials
might modify this attitude in the coming years.
Level of evidence: V
Strength of recommendation: E
Consensus: 100% yes (23 voters)
3. The potential role of COO determination by IHC
or GEP as a prognostic tool
DLBCL is the most common form of lymphoma in the Western
world [63]. It shows a wide spectrum of morphology and is bio-
logically heterogeneous [63]. To identify biological entities
within DLBCL, GEP has been applied to tumour samples of
DLBCL [64–66]. The seminal study by Alizadeh et al. [64] was
the first to recognise that DLBCL contains at least two biological
entities, one with a GEP similar to the normal purified germinal
centre B-cell (the germinal centre B-cell profile, or GCB) and
the other similar to the profile produced by a purified, in vitro
immunoglobulin M (IgM)-stimulated B-cell (the activated B-
cell profile, or ABC). Consequently, DLBCL was commonly
divided into these two subtypes, which show different clinical
and molecular features. The robustness of this profile based on
GEP has been confirmed in other studies [67–69].
As the use of high-throughput GEP was considered unfeasible
in routine laboratory practice, there have been several attempts
to simplify the procedures for COO determination. These
attempts have gone in two directions, namely the identification
of IHC surrogates and the application of GEP (either high-
throughput or low-throughput) to formalin-fixed and paraffin-
embedded (FFPE) samples.
Several IHC surrogate protocols use an algorithm to identify
the COO in FFPE samples of DLBCL. Several algorithms have
been published, including those by Colomo et al. [70], Hans
et al. [71], Muris et al. [72], Choi et al. [73], Nyman et al. [74],
Natkunam et al. [75], Meyer (better known as ‘Tally’) et al. [76]
and Visco et al. [77]. Although these seem to work well as sur-
vival predictors when samples are stained and analysed in a
single centre, the results are not easily transferrable to other la-
boratories [78–80]. Indeed, data from a large randomised clinic-
al trial [81] and a meta-analysis have shown a limited role for
IHC algorithms [82].
Given the limitations of IHC in terms of COO signature re-
producibility, several groups have attempted to use FFPE as a
source of RNA to identify the COO signature by high-through-
put [83, 84] or low- to medium-throughput GEP techniques
[85–91]. The results have been much more robust than those
obtained by IHC, and findings from a meta-analysis have con-
firmed the usefulness of GEP approaches [82]. Most studies
were retrospective, but two phase III clinical trials incorporating
COO GEP on FFPE samples, namely the REMoDL-B study
(ClinicalTrials.gov identifier NCT01324596 [92]), which uses
the Illumina DASL platform (Illumina Inc., San Diego, CA),
and the ROBUST study (ClinicalTrials.gov identifier
NCT02285062 [93]), which uses the Nanostring nCounter-
based Lymph2Cx platform (NanoString Technologies, Seattle,
WA), are ongoing [94].
Against this background, the panel members discussed the
adequacy for clinical use of COO-determining methods in
DLBCL by both IHC and GEP.
methodological considerations
broad availability: IHC is widely available. Conversely, GEP
technologies are currently limited to very specialised laboratories.
The introduction of more user-friendly technologies (such as
Nanostring nCounter) might render GEP more widely available
and applicable in routine clinical practice in the near future.
reproducibility: IHC suffers from major reproducibility issues,
which include inter-laboratory and inter-observer concordance,
varying degrees of overlap with the gold standard GEP
techniques and often poor correlation between the various
algorithms available [78–82]. GEP using well-established high-
throughput commercial chips is robust; however, inter-laboratory
variability needs to be explored. So far, only one study using the
Nanostring-based Lymph2Cx assay has assessed inter-laboratory
agreement, with excellent results; the same test also showed
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excellent concordance for resampled biopsies and between
different reagent lots [88, 91]. However, processing of samples
would critically influence the outcome of GEP results and so
particular care should be devoted to pre-analytical variables.
clarity of reporting systems: The reporting system for IHC
has been standardised, with algorithms to clearly specify
thresholds and procedures (e.g. the Hans classifier uses a 30%
positive cell cut-off and a step-by-step algorithm), although few
pathology reports specify the exact percentage of positive cells
or even the algorithm used. For GEP, no standardised system for
the interpretation of data or reporting of results is available.
prognostic value
The limitations of IHC algorithms have been described earlier.
The panel also raised substantial concerns regarding the
prognostic value of IHC. Conversely, several published studies
support the general prognostic value of COO assessment by
GEP in DLBCL, and so the panel was more confident in
supporting this technical approach for prognostication [I, A]
[82]. These considerations are particularly relevant with regard
to drugs, which promise differential activity in germinal centre
B-cell-like versus activated B-cell-like DLBCLs.
panel recommendations for the use of COO identification by IHC
and GEP in clinical trials for monitoring and intervention
recommendation 3.1: Given the limitations of IHC, the
panel does not encourage its use in prospective clinical trials for
prognostication.
Level of evidence: I
Strength of recommendation: C
Consensus: 100% yes (23 voters)
recommendation 3.2: Given the limitations of IHC, the
panel discourages its use in prospective clinical trials to guide
intervention.
Level of evidence: I
Strength of recommendation: D
Consensus: 100% yes (23 voters)
recommendation 3.3: The panel strongly encourages the use
of GEP in prospective clinical trials for prognostication.
Level of evidence: I
Strength of recommendation: A
Consensus: 100% yes (23 voters)
recommendation 3.4: Clinical trials of interventions based
on GEP results are encouraged.
Level of evidence: I
Strength of recommendation: B
Consensus: 100% yes (23 voters)
panel recommendations for the use of COO identification by IHC
and GEP for monitoring and intervention in routine clinical
practice
recommendation 3.5: Based on inadequate standardisation,
and a lack of well-designed interventional studies, the use of
COO determination by IHC or GEP in DLBCL is generally not
recommended in routine clinical practice outside of clinical
trials.
Level of evidence: V
Strength of recommendation: D
Consensus: 100% yes (23 voters)
4. MRD evaluation by polymerase chain reaction-
based methods and flow cytometry
MRD assessment can be used for the identification of different
prognostic subgroups in patients with B-cell lymphomas and
CLL, and is an excellent surrogate for treatment outcome [95–
99]. Published evidence for the prognostic impact of MRD
exists for MCL [96, 100, 101], FL [95, 96, 98, 102, 103] and CLL
[97, 104–107]. In these entities, achievement of MRD response
by conventional or intensified treatment is associated with pro-
longed progression-free survival (PFS) and OS independent of
categorical response assessment and a favourable prognosis.
Several prospective phase III trials using standardised
approaches for MRD assessment have been published and dem-
onstrate the prognostic relevance of MRD response in FL, MCL
and CLL independently of treatment regimen or strategy and
clinical risk parameters [95–99]. Indeed, the prognostic impact
of MRD status has led to MRD being proposed as a secondary
end point in ongoing clinical trials. In CLL, recent evidence sug-
gests that MRD might also be used to identify candidates for
dose de-escalations. Therefore, polymerase chain reaction
(PCR)-based MRD evaluation is considered a promising prog-
nosticator in MCL and FL, whereas MRD evaluation by flow
cytometry is preferred in CLL.
methodological considerations
broad availability: Flow cytometry is generally available in
Europe for CLL, but standardised four-colour flow to detect
MRD at a level of 10-4 is only available in specialised
institutions; real-time quantitative (RQ)-PCR is only available in
specialised centres (EUROMRD network; www.euromrd.org).
reproducibility and standardisation: For RQ-PCR,
reproducibility is excellent and methods are standardised and
subjected to periodic quality controls at specialised institutions
involved in the EURO MRD network. Flow-based MRD
methods are currently harmonised, but not standardised, and
inter-laboratory reproducibility has not been systematically
assessed.
clarity of reporting systems: Reporting of molecular MRD
results is standardised within established networks. Flow
cytometry standardisation is currently ongoing within the
EuroFlow network (http://www.euroflow.org).
prognostic value
The panel is confident of the general prognostic value of MRD
evaluation in MCL [I, A], FL [I, A] and CLL [I, A].
Several phase III clinical trials have been carried out in FL
[95, 102, 108, 109], CLL [97, 110, 111] and MCL [96] that
clearly demonstrate the usefulness of MRD as a surrogate end
point for monitoring treatment efficiency and for its prognostic
value. Remarkably, in all three entities, the prognostic impact of
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MRD response on PFS and OS has been documented independ-
ent of treatment regimen, mostly in both peripheral blood and
bone marrow.
panel recommendations for the use of MRD evaluation in clinical
trials for monitoring and intervention
The panel felt confident that MRD monitoring of treatment
response as an end point in clinical trials might facilitate the
interpretation of results. Whether trials investigating MRD-
based treatment tailoring might lead to substantial therapeutic
improvement and treatment optimisation is an attractive but as
yet unproven possibility. MRD assessment post-induction
therapy is the most frequently assessed time point for MRD
response as it is associated with a high prognostic impact and is
therefore suitable to guide treatment intervention. Later time
points during treatment are also of prognostic value and are
suitable to guide treatment intervention. However, so far, only
one clinical trial in CLL has been published, which showed that
MRD-based intervention (in terms of discontinuation of
treatment once MRD negativity was seen) was associated with
comparable PFS and OS independent of the number of courses
of treatment received [110]. The panel therefore decided that
more data are required to support the clinical benefit of
treatment modification based on efficacy, as determined by
MRD negativity.
recommendation 4.1: The use of MRD evaluation for
monitoring and intervention in clinical trials is encouraged in
MCL, FL and CLL:
(i) MCL: for monitoring [112, 113]:
Level of evidence: I
Strength of recommendation: B
(ii) MCL: for intervention [112, 113]:
Level of evidence: III
Strength of recommendation: C
(iii) FL: for monitoring [113]:
Level of evidence: I
Strength of recommendation: B
(iv) FL: for intervention [113]:
Level of evidence: IV
Strength of recommendation: C
(v) CLL: for monitoring (depends on the drug used):
Level of evidence: I
Strength of recommendation: B
(vi) CLL: for intervention:
Level of evidence: IV
Strength of recommendation: C
Consensus: 100% yes (23 voters)
panel recommendations for the use of MRD for monitoring and
intervention in routine clinical practice
The panel does not support MRD evaluation for monitoring
or intervention in routine practice outside of clinical trials as
there is no general recommendation for treatment modification
currently published. However, results of ongoing trials might
modify this attitude in the coming years. The only exception is
MRD assessment after allo-SCT, where it is a useful tool to
monitor lymphoma regrowth and is more sensitive than
currently used short tandem repeat analysis. In this setting,
MRD can be used for discontinuation or intensification of
immunosuppression [114].
recommendation 4.2: The use of MRD evaluation for
monitoring and intervention in clinical practice is not
recommended in MCL, FL and CLL, with the exception of
monitoring after allo-SCT.
Level of evidence: V
Strength of recommendation: D
Consensus: 100% yes (23 voters)
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